Chapter category: Vaccines
Cancer Peptide Vaccines in Clinical Trials
Peptide-Based Cancer Vaccines
Edited by: W. Martin KastISBN: 1-58706-026-4
» Get more information about this book at landesbioscience.com «
Chapter authors:
Jeffrey S. Weber
The revelation that protein antigens were processed into peptides by a pathway of intracellular degradation and presented on the surface of antigen presenting cells for recognition by T-cells in association with class I and II MHC molecules created a new paradigm for the generation and detection of antigen-specific immune responses in humans.1-3 The subsequent discovery, cloning and identification of several classes of tumor-associated and tumor-specific antigens from human melanomas and other cancers has facilitated the performance of a number of clinical trials of peptide vaccines with and without adjuvants in patients with metastatic and resected melanoma and several other malignancies and pre-cancerous conditions. In this review I will summarize the different classes of melanoma and human papillomavirus (HPV) antigens that have been defined and describe the available data on recent attempts to boost immunity directed against defined melanoma and HPV antigens using peptides and detail their clinical significance. I will conclude with a proposal for an “optimal” vaccine schema and a call for an expansion of current peptide vaccine efforts in melanoma and other histologies.
Additional chapters from this book:
Melanoma Peptide Clinical Trials
Ian D. Davis and Michael T. Lotze
Although various immunologic approaches to the treatment of cancer have been used for over a century,1 it is only relatively recent that specific human cancer targets have been defined allowing spec...
Gp100 and G250: Towards Specific Immunotherapy Employing Dendritic Cells in Melanoma and Renal Cell Carcinoma
Joost L.M.Vissers, I. Jolanda M. de Vries, Egbert Oosterwijk, Carl G. Figdor and Gosse J. Adema
A long history of studies demonstrate the capacity of the immune system to develop specific reactivity against antigens foreign to the host, like viral and bacterial antigens. During the last decade...
Peptide Vaccines for the Treatment of Melanoma
Willem W. Overwijk and Nicholas P. Restifo
The development of cancer vaccines has been greatly advanced by the recent identification of many tumor-associated antigens (TAA) recognized by T cells.1,2 A majority of these antigens have been clo...
Peptides in Cervical Cancer
Maaike E. Ressing, Remco M.P. Brandt, Joan H. de Jong, Rienk Offringa, Cornelis J.M. Melief and W. Martin Kast
Observations that susceptibility to several cancer types is increased in immunocompromised individuals have led to the assumption that immune responses are able to interfere with tumor development.1...
Peptides in Prostate Cancer
Michael L. Salgaller
The timely detection and effective treatment of prostatic cancer is one of the major health problems faced in the United States and, to a comparable extent, the rest of the world. It is predicted th...
Clinical Trials of HER-2/neu Peptide-Based Vaccines
Mary L. Disis and Martin A. Cheever
Cancer vaccines are not used routinely in the clinical practice of most oncologists, despite decades of study. Several advances in basic immunology over the last few years have forced a re-evaluatio...
Cytotoxic T Cell Epitopes and Tissue Distribution of the HER-2/neu Proto-Oncogene: Implications for Vaccine Development
Barbara Seliger, Koji Kono, Y. Rongcun and Rolf Kiessling
The development of immunotherapeutic methods to treat cancer is critically depen dent on the identification of tumor-associated antigens (TAA). Several immunodominant peptide epitopes, recognized by...
Studies of MUC1 Peptides
Vasso Apostolopoulos, Geoffrey A. Pietersz and Ian FC McKenzie
There have been more studies of Mucin 1 (MUC1) peptides in breast cancer than of any other peptides in this disease, and it is appropriate that the use of MUC1 peptides and vaccines be reviewed here...
Carcinoembryonic Antigen (CEA) Peptides and Vaccines for Carcinoma
Jeffrey Schlom
This Chapter addresses the current status of the development of recombinant vaccines employing carcinoembryonic antigen (CEA) as the target antigen. Included is an over view of preclinical studies a...
Cancer Peptide Vaccines in Clinical Trials
Jeffrey S. Weber
The revelation that protein antigens were processed into peptides by a pathway of intracellular degradation and presented on the surface of antigen presenting cells for recognition by T-cells in ass...
Critical Dependence of the Peptide Delivery Method on the Efficacy of Epitope Focused Immunotherapy
Gregory E. Holt, Markwin P. Velders, Michael P. Rudolf, Laurie A. Small, Maurizio Provenzano, Sanne Weijzen, Diane M. Da Silva, Marten Visser, Simone A.J. ter Horst, Remco M.P. Brandt and W. Martin Kast
Tumor immunotherapy describes the use of the immune system as a tool to eliminate cancer from the stricken patient. The theory contends that immunization against certain proteins either associated w...
p53: A Target for T-Cell Mediated Immunotherapy
Michel P.M. Vierboom, Dmitry I. Gabrilovich, Rienk Offringa, W. Martin Kast and Cornelis J.M. Melief
Burnet’s theory of immunosurveillance postulates that malignant transformation causes the expression of neoantigens. The theory states tumor specific antigens are recognized by the immune system, ...
Mutant Oncogene and Tumor Suppressor Gene Products and Fusion Proteins Created by Chromosomal Translocations as Targets for Cancer Vaccines
V. Ellen Maher, B. Scott Worley, David Contois, M. Charles Smith, Michael J. Kelley, Michael Stipanov, Samir N. Khleif, Theresa Goletz, Leon van den Broeke, Crystal Mackall, Lee J. Helman, David P. Carbone and Jay A. Berzofsky
Identification and Selection of T-Cell Epitopes Derived from Tumor-Associated Antigens for the Development of Immunotherapy for Cancer
Esteban Celis
Because the immune system has the capacity to recognize and in many cases destroy tumor cells, significant efforts are being devoted to the development of immune-based therapies for cancer. Both cyt...
